L05 #ACR22 High-dose Denosumab in Erosive Hand OA 48Wk, Double-blind PBO Phase 2 100 patients GUSS change higher in DEN v PBO at w24, incr at w48 New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001) Open label extension w improvement to baseline @RheumNow https://t.co/X6MF9q2bKj

This single ctr retrospective cohort study by AOhayn on antiRo/La+ moms show that the mean timing of first fetal echo for CHB screening was at 20wks AOG. 💠CHB+ in 3 fetuses on 1st echo (done 19, 22.4, 29.3 wks) Take home msg? Do timely CHB screens #ACR22 @RheumNow ABST#0957 https://t.co/59crW0uov4

Walrabenstein et al. RCT of 16-week triple intervention - plant-based diet, exercise, stress management - vs usual care in OA. It works, but we don't know which component, or if Hawthorn effect @RheumNow #ACR22 Abstr#1644 https://t.co/p74Ptd8bZ2 https://t.co/EOg7RxRmO7

• Effect of a Lifestyle Program Based on a Whole Food Plant-based Diet, Physical …

Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events. @RheumNow #ACR22 #LateBreaking

Fletcher et al. Epidemiology RA-ILD 2004-18 in VA. Incidence increased from 340 to 970/100,000PY. Prevalence increased 1.7% to 4.5%. More common males (4.81% vs 2.53%) and over 60 @RheumNow #ACR22 Abstr#1638 https://t.co/AbPgLUPoDz https://t.co/V25xDUwLbu

• Epidemiology of Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung…

Askanase et al. Phase 2 RCT Cenerimod (S1P modulator) in SLE. Primary endpoint not met. Some suggestion of efficacy at highest 4mg dose. But if its already like this in a phase 2, I doubt a phase 3 will bring better results @RheumNow #ACR22 Abstr#1656 https://t.co/p4fcKW3cYD https://t.co/ha8xqeW6Xk

• Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic L…

@RheumNow Assessing CV events in hierarchical order (each level has additional CV event). Hypothesis that increased CV events are driven by VTE in all-comers with the 10mg dose. https://t.co/IfRdJBERuA

L06 #ACR22 ORAL Surveillance Updates! Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi But, MACE numerically higher with Tofa w/ h/o ASCVD Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk Most important risk is pt's individual risks @RheumNow https://t.co/jPPX7f5GRE

Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA: ❗Pre-conceptional NSAID use ❗Age Thought-provoking. Time to re-evaluate our NSAID prescribing practices for ♀️ SpA? #ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe

This single ctr retro cohort study by Dr ZKazmi showed ⬇️HPV vax rates & ⬆️HPV infxn rates 🔅In HPV+ pts, risk of persistent HPV infxn was similar among ♀️ aged 21-26y & 27-45y (p>0.05) Is it time for updated cervical ca screening guidelines for #lupus? #ACR22 @RheumNow ABST#1671 https://t.co/7Nh62EYc6Y

Interesting study (MAGICA) of withdrawing TCZ in GCA after 1 year of therapy Comparing abrupt vs gradual discontinuation Very important clinical quesiton; kudos to FVSG for making this happen! #ACR22 #Vasculitis22 @RheumNow https://t.co/912GCFik6L

McCarter et al. RA patients intiating ICI. 46% risk of flare, happens quickly (27% in first 28 days) and then plateaus. Seropositive higher risk HR 1.95. No difference in mortality. @RheumNow #ACR22 Abstr#1667 https://t.co/o9SKdNAYcE https://t.co/FmN89LAggG

• Pre-existing Rheumatoid Arthritis Patients Initiating Immune Checkpoint Inhibit…

Ab1671 #ACR22 Cervical Cancer screening in SLE 106 SLE patients, mean age 40. Only 3.7% w HPV vax! 24% abnml PAP, 30% HPV infection HPV highest in 21-26 yo (83%) vs 27-45 (35%) ASCUS 50% HPV+, 1 pt squamous cell ca Recs: HPV Vax💉, test HPV as high positivity @RheumNow @KDAO2011 https://t.co/nHlvGVVm40